Agilent Technologies has announced the launch of a CGP assay designed for somatic variant profiling. The technology, called Agilent SureSelect Cancer CGP, will help scientists profile a wider range of tumour samples by improving workflow efficiency and reducing hands-on time.

The pan-cancer assay is based on a next-generation sequencing (NGS) panel of 679 genes amalgamated from cancer databases and research partnerships.

According to the California, US-based laboratory technology company, the launch of the assay will make tumour molecular profiling more accessible to the clinical research community.

The biomarkers include a range of somatic variants and immune-oncology markers such as TMB (tumor mutational burden) and MSI (microsatellite instability). The incorporation of walkaway automation will improve lab efficiency and workflow, Agilent said.

The NGS market was valued at $42m in 2022 by GlobalData. NGS is at the forefront of oncological research, aiming to provide personalised treatment to patients by identifying specific genetic mutations. Technological advancements in this area will be important in accelerating treatment options to patients and identifying drugs that should not be used. Remove rate-limiting steps and making profiling more efficient is critical in field where rates of most cancer types are increasing.

“We’re pleased to commercialise the SureSelect Cancer CGP assay, which leverages our SureSelect chemistry that can accommodate a low amount of starting material so that scientists can profile more quantity-limited samples,” explained Ronda Allen, Ph.D., vice president and general manager, Genomics Division at Agilent.

“Library preparation and target enrichment can be automated either on the benchtop Magnis NGS prep system which will markedly improve workflow efficiency, reducing the hands-on time from hours to only 15 minutes, or on the Bravo NGS workstation, for scaling up to 96 samples per run.”